Paper Details

  1. Home
  2. Paper Details

Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.

Author: ArnoldDouglas L, Castro-BorreroWanda, ChenHailu, DrulovicJelena, FreedmanMark S, GoldRalf, GudesblattMark, Hernandez PerezMiguel Angel, JasinskaElzbieta, LaGankeChristopher C, LevinSeth, NaismithRobert T, NegroskiDonald, OhJiwon, ScaramozzaMatthew, SelmajKrzysztof, ShankarSai L, SingerBarry A, Then BerghFlorian, WangTing, WraySibyl, WundesAnnette, ZiemssenTjalf

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Diroximel fumarate (DRF) is approved for the treatment of multiple sclerosis (MS) and has been shown to have fewer gastrointestinal (GI) side effects compared to dimethyl fumarate (DMF).
Paper Details　
Original Abstract of the Article :
Diroximel fumarate (DRF) is approved for adults with relapsing-remitting multiple sclerosis (RRMS) in Europe and for relapsing forms of MS in the United States. DRF and dimethyl fumarate (DMF) yield bioequivalent exposure of the active metabolite monomethyl fumarate. Prior studies indicated fewer ga...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687803/

データ提供：米国国立医学図書館（NLM）

Diroximel Fumarate: A New Hope for Relapsing-Remitting Multiple Sclerosis?

Multiple sclerosis (MS) is a chronic inflammatory disease that affects the central nervous system. This study examines the safety and efficacy of diroximel fumarate (DRF), a new oral medication, for treating relapsing-remitting MS (RRMS). The authors analyzed data from a Phase 3 clinical trial, comparing DRF to dimethyl fumarate (DMF), another medication used for MS. Like a skilled physician searching for a new cure, the researchers investigate the potential of DRF to provide relief for patients suffering from RRMS.

DRF: A Potential Breakthrough in RRMS Treatment?

The study suggests that DRF may be an effective and well-tolerated treatment option for RRMS, potentially offering benefits over DMF in terms of gastrointestinal side effects.

A New Frontier: Seeking Improved Treatment Options for MS

This research highlights the ongoing search for new and improved therapies for MS, particularly for those experiencing relapsing-remitting disease. It underscores the importance of clinical trials in evaluating the safety and efficacy of new treatments.

Dr.Camel's Conclusion

This study explores the potential of DRF as a new treatment option for RRMS. It provides valuable data that may pave the way for better management of this complex and often debilitating disease.

Date :
  1. Date Completed 2023-11-30
  2. Date Revised 2023-12-01
Further Info :

Pubmed ID

37905526

DOI: Digital Object Identifier

PMC10687803

Related Literature

Article Analysis
・Effects of monomethyl fumarate
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.